JP2011528366A - （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法 - Google Patents

（２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法 Download PDF

Info

Publication number
JP2011528366A
JP2011528366A JP2011518868A JP2011518868A JP2011528366A JP 2011528366 A JP2011528366 A JP 2011528366A JP 2011518868 A JP2011518868 A JP 2011518868A JP 2011518868 A JP2011518868 A JP 2011518868A JP 2011528366 A JP2011528366 A JP 2011528366A
Authority
JP
Japan
Prior art keywords
chloro
phenyl
pyran
tetrahydro
methylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518868A
Other languages
English (en)
Japanese (ja)
Inventor
ポール スーザン マーガレット デュ
アネット ペルルベルク
マシュー マンチュ ツァオ
Original Assignee
レクシコン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レクシコン ファーマシューティカルズ インコーポレイテッド filed Critical レクシコン ファーマシューティカルズ インコーポレイテッド
Publication of JP2011528366A publication Critical patent/JP2011528366A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2011518868A 2008-07-17 2009-07-15 （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法 Pending JP2011528366A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8142308P 2008-07-17 2008-07-17
US61/081,423 2008-07-17
PCT/US2009/050636 WO2010009197A1 (en) 2008-07-17 2009-07-15 Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015193990A Division JP6283337B2 (ja) 2008-07-17 2015-09-30 （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法

Publications (1)

Publication Number Publication Date
JP2011528366A true JP2011528366A (ja) 2011-11-17

Family

ID=41137707

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011518868A Pending JP2011528366A (ja) 2008-07-17 2009-07-15 （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法
JP2015193990A Active JP6283337B2 (ja) 2008-07-17 2015-09-30 （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015193990A Active JP6283337B2 (ja) 2008-07-17 2015-09-30 （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法

Country Status (29)

Country Link
US (2) US8217156B2 (da)
EP (1) EP2332947B1 (da)
JP (2) JP2011528366A (da)
KR (2) KR101707246B1 (da)
CN (2) CN107629097A (da)
AR (1) AR072807A1 (da)
AU (1) AU2009270973B2 (da)
BR (1) BRPI0916191A2 (da)
CA (1) CA2730931A1 (da)
CL (1) CL2009001595A1 (da)
CO (1) CO6351797A2 (da)
DK (1) DK2332947T3 (da)
ES (1) ES2656357T3 (da)
HK (1) HK1243713A1 (da)
HU (1) HUE035400T2 (da)
IL (1) IL210269A (da)
MX (1) MX2011000503A (da)
NO (1) NO2332947T3 (da)
NZ (1) NZ590184A (da)
PE (1) PE20100260A1 (da)
PL (1) PL2332947T3 (da)
PT (1) PT2332947T (da)
RU (1) RU2505543C2 (da)
SG (1) SG185317A1 (da)
TW (1) TWI472521B (da)
UA (1) UA106048C2 (da)
UY (1) UY31992A (da)
WO (1) WO2010009197A1 (da)
ZA (1) ZA201100175B (da)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504285A (ja) * 2012-11-20 2016-02-12 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウムグルコース共輸送体１の阻害剤
JP2019516804A (ja) * 2016-05-25 2019-06-20 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
CA2694029C (en) 2007-07-26 2016-10-04 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法
TWI562775B (en) * 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102453026A (zh) 2010-10-27 2012-05-16 上海艾力斯医药科技有限公司 C-芳基葡糖苷衍生物、制备方法及其应用
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
US20210317140A1 (en) 2013-10-18 2021-10-14 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
KR102590696B1 (ko) 2015-07-30 2023-10-18 자이단호진 비세이부쯔 가가꾸 겡뀨까이 다제 내성균에 유효한 신규한 아미노글리코시드 항생 물질
WO2018067805A1 (en) 2016-10-06 2018-04-12 Teva Pharmaceutical Industries Ltd. Solid state forms of sotagliflozin
US20210212968A1 (en) 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2019254371A1 (en) 2018-04-17 2020-10-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN110818722B (zh) * 2018-08-14 2022-12-02 苏州鹏旭医药科技有限公司 三种化合物及其制备方法和在合成索格列净中的用途
WO2020068661A1 (en) * 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
CN109824687B (zh) * 2019-03-26 2022-03-22 上海凌凯医药科技有限公司 呋喃木糖衍生物的新合成方法
US20220324897A1 (en) * 2019-07-05 2022-10-13 Shandong Danhong Pharmaceutical Co., Ltd. Crystal form of sglt inhibitor and application thereof
EP3771718A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Process for preparing the crystalline form ii of sotagliflozin
EP3771480A1 (en) 2019-08-01 2021-02-03 Lexicon Pharmaceuticals, Inc. Continuous process for preparing the crystalline form ii of sotagliflozin
US20240100013A1 (en) 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
WO2022155303A1 (en) 2021-01-14 2022-07-21 Lexicon Pharmaceuticals, Inc. Sotagliflozin for treating or preventing cardiovascular diseases
CN113880701A (zh) * 2021-10-10 2022-01-04 浙江司太立制药股份有限公司 一种抗糖尿病药物中间体及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2008042688A2 (en) * 2006-09-29 2008-04-10 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2009014970A1 (en) * 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870699A (en) * 1973-03-06 1975-03-11 Upjohn Co Lincomycin analogs
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE445608T1 (de) 2005-02-23 2009-10-15 Boehringer Ingelheim Int Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
CN1820858A (zh) * 2006-03-10 2006-08-23 广西中医学院制药厂 多相物料喷雾方法及装置
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TWI472521B (zh) 2008-07-17 2015-02-11 Lexicon Pharmaceuticals Inc （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519698A (ja) * 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
WO2008042688A2 (en) * 2006-09-29 2008-04-10 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
WO2009014970A1 (en) * 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"新医薬品の規格及び試験方法の設定について", 医薬審発第５６８号, JPN6010021254, 2001, ISSN: 0002869575 *
大島寛: "結晶多形・擬多形の析出挙動と制御", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0002869576 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0002869578 *
最新創薬化学下巻, JPN6014000634, 1999, pages 452 - 453, ISSN: 0002721588 *
有機化合物結晶作製ハンドブック, JPN6014000636, 2008, pages 11 - 57, ISSN: 0002721589 *
生活工学研究, vol. ４, JPN6014015069, 2002, pages 310 - 317, ISSN: 0002869574 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0002869577 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504285A (ja) * 2012-11-20 2016-02-12 レクシコン ファーマシューティカルズ インコーポレイテッド ナトリウムグルコース共輸送体１の阻害剤
JP2019516804A (ja) * 2016-05-25 2019-06-20 クリスタル ファーマシューティカル（スーチョウ）カンパニー，リミテッド ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途

Also Published As

Publication number Publication date
AU2009270973B2 (en) 2014-01-30
NZ590184A (en) 2012-09-28
US20130165395A1 (en) 2013-06-27
RU2011105797A (ru) 2012-08-27
US8217156B2 (en) 2012-07-10
UY31992A (es) 2010-02-26
ZA201100175B (en) 2012-03-28
IL210269A0 (en) 2011-03-31
SG185317A1 (en) 2012-11-29
PE20100260A1 (es) 2010-04-16
US20100016422A1 (en) 2010-01-21
CO6351797A2 (es) 2011-12-20
DK2332947T3 (da) 2018-01-29
CA2730931A1 (en) 2010-01-21
PT2332947T (pt) 2018-02-06
HK1243713A1 (zh) 2018-07-20
EP2332947A1 (en) 2011-06-15
KR20170010069A (ko) 2017-01-25
IL210269A (en) 2015-06-30
JP2016041701A (ja) 2016-03-31
AU2009270973A1 (en) 2010-01-21
BRPI0916191A2 (pt) 2017-08-29
US9067962B2 (en) 2015-06-30
TWI472521B (zh) 2015-02-11
CN102112483A (zh) 2011-06-29
CN107629097A (zh) 2018-01-26
EP2332947B1 (en) 2017-11-01
PL2332947T3 (pl) 2018-04-30
UA106048C2 (uk) 2014-07-25
AR072807A1 (es) 2010-09-22
KR20110031196A (ko) 2011-03-24
CL2009001595A1 (es) 2010-07-19
RU2505543C2 (ru) 2014-01-27
TW201006808A (en) 2010-02-16
JP6283337B2 (ja) 2018-02-21
ES2656357T3 (es) 2018-02-26
HUE035400T2 (en) 2018-05-02
WO2010009197A1 (en) 2010-01-21
MX2011000503A (es) 2011-03-01
NO2332947T3 (da) 2018-03-31
KR101707246B1 (ko) 2017-02-15

Similar Documents

Publication Publication Date Title
JP6283337B2 (ja) （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（４−クロロ−３−（４−エトキシベンジル）フェニル）−６−（メチルチオ）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールの固体形態及びその使用方法
US8026347B2 (en) Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
KR101837488B1 (ko) 광학적으로 순수한 벤질-4-클로로페닐-c-글루코사이드 유도체
BE897516A (fr) Nouveaux derives de la desoxyuridine leur preparation et leur utilisation comme medicaments
US10703772B2 (en) Processes for the preparation of SGLT-2 inhibitors, intermediates thereof
JPH0536436B2 (da)
US11548906B2 (en) Processes for the preparation of SGLT-2 inhibitors, intermediates thereof
AU2013206276A1 (en) Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140408

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150602